Loading the section…

BNR: financial statements from SEC — TradeAlmanac

BNR

Burning Rock Biotech Limited: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024	31/12/2023	31/12/2022
Revenue	540M	71M	537M	563M
Cost of revenue	137M	153M	174M	183M
Gross profit	403M	50M	363M	380M
Research and development	166M	232M	347M	422M
Selling, general and administrative	126M	36M	438M	568M
Operating income	−55M	−358M	−669M	−980M
Pre-tax income	−54M	−341M	−651M	−969M
Income tax	2M	806,000	2M	2M
Net income	−55M	−347M	−654M	−971M
Earnings per share	−0.52	−3.37	−6.38	−9.35
Earnings per share, diluted	−0.52	−0.46	−6.38	−9.35
Weighted average shares	89M	86M	85M	87M
Weighted average shares, diluted	89M	86M	85M	87M

Balance sheet

Metric	19/08/2026	18/08/2026	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021
Cash and equivalents	—	—	478M	520M	615M	905M	1.44B
Receivables	—	—	170M	152M

Cash flow

Metric	31/12/2025	31/12/2024	31/12/2023	31/12/2022
Operating cash flow	−28M	−13M	−256M	−457M
Depreciation and amortisation	22M	7M	133M	124M
Share-based compensation	14M	156M	261M	327M
Capital expenditure

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator